Treatment of Cervicogenic Headache
Posted on October 04 2022,
This post is for educational purposes only and may contain errors. Please talk to your neurologist.
The treatment of cervicogenic headache should involve the patient, allowing them to be an active participant in the decision-making process.
First-line treatment
Physical therapy
- Spinal joint manipulation and/or mobilization
- Soft tissue manipulation focusing on the myofascial trigger points of the sternocleidomastoid muscle
- Muscle endurance and strength training focusing on deep cervical flexor muscles
- Do NOT perform high-velocity low amplitude manipulation therapy (neck cracking) due to risk of stroke
There may be discomfort immediately post therapy.
Pharmacological options
- Pregabalin (https://pubmed.ncbi.nlm.nih.gov/25373811/)
- Duloxetine (not studied for cervicogenic headache)
- Gabapentin (not studied for cervicogenic headache)
- Tricyclic antidepressants (not studied for cervicogenic headache)
Procedures
- Anesthetic blockade of the lateral atlanto-axial joint, the C2-3 zygapophyseal joint (and the overlying third occipital nerve), and/or the C3-4 zygapophyseal joint. This may also allow patients to be able to handle physical therapy better. Moreover, an occipital nerve block may also be done, but the logic isn’t sound because cervicogenic headache is referred pain from the neck.
- Radiofrequency ablation of C2 dorsal root ganglion and/or third occipital nerve.
- Coblation (https://pubmed.ncbi.nlm.nih.gov/30561695/)
- Glucocorticoid injections. Options include atlantoaxial joint injection, C2-C3 zygapophyseal joint injection, and cervical spinal nerve root block (in patients with cervical spondylotic radiculopathy).
- Neuromodulation (https://pubmed.ncbi.nlm.nih.gov/29178511/)
- Surgery (only if there is an obvious reason on imaging that necessitates it)
Other:
Alternative medicine: dry needling
Mon, Nov 17, 25
Migraine Research - During the week of my absence.
Migraine Research - During the week of my absence. The Association Between Insomnia and Migraine Disability and Quality of Life This study examined how insomnia severity relates to migraine disability...
Read MoreSat, Nov 01, 25
Anti-CGRP Monoclonal Antibody Migraine Treatment: Super-Responders and Absolute Responders and When to Expect Results
Anti-CGRP monoclonal antibodies achieved 70% super-response and 23% complete migraine freedom in a one-year study. Most dramatic improvements occurred after 6 months of treatment. For patients with chronic or high-frequency...
Read MoreAll Non-Invasive Neuromodulation Devices for Migraine Treatment
Wondering if migraine devices actually work? This guide breaks down the latest evidence on non-invasive neuromodulation devices like Cefaly, Nerivio, and gammaCore. Learn which devices have solid research backing them,...
Read More
